嘉和生物－Ｂ (6998.HK)

1.250 -0.030 (-2.34%) 收市：04:08PM HKT

嘉和生物－Ｂ

Building 3
1690 Zhangheng Road Pudong New District
Shanghai 201203
China
86 21 6169 0700
https://www.genorbio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 104

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Feng Guo Ph.D.	CEO & Chairman	7.95M	無	1970
Mr. Chengyi Weng	Vice President of Finance	無	無	無
Mr. Qibin Liang	Chief Technology Officer	無	無	1957
Dr. Shuhua Han Ph.D.	Chief Scientist	無	無	1959
Ms. Xiaojing Zhu	Vice President of Compliance & Administration	無	無	無
Mr. Tong Li M.D.	Chief Medical Officer	無	無	1969
Mr. Tak Wai Ip	Company Secretary	無	無	無
Mr. Jun Lin	Vice President of Quality Analysis	無	無	1985
Mr. Qingtang Duan	General Manager of Yuxi Genor	無	無	1983

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn's disease, and fistulising crohn's disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating hormone receptor-positive (HR+)/HER2- breast cancer and is under Phase III clinical trials; and GB492, a stimulator of interferon genes (STING) agonist expected to exert synergistic effects in combination with GB226 for solid tumors and is under Phase 1/2 clinical trial. Further, it develops GB221, a herceptin (trastuzumab)-mimic HER2 monoclonal antibody (mAb) drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb drug candidate, which is under Phase I clinical trial; and GB261 to treat B-cell non-Hodgkin Lymphoma and is under Phase I Clinical trials. In addition, the company's product candidates under clinical trials include GB262, GB264, GB267, and GB266 for the treatment of cancer. The company was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.

公司管治

截至 無 止，嘉和生物－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。